Cerus

CERS · NASDAQ

$2.31+$0.09 (+4.05%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $2.22

CERS analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $5.23 (+126.3% upside)

Low: $4.04
Now: $2.31
High: $6.82

Upgrades and downgrades

The latest rating actions, newest first

CERS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Broker	Aug 20, 2026	Initiates	Buy	$6.50	—
BTIG	May 1, 2026	Upgrade	Neutral → Buy	$4.00	54%

The case for and against

Updated Oct 30, 2024

Bull case

Cerus Corp. has demonstrated steady financial performance, with total product revenue growing approximately 0.5% year-over-year to $39.8 million, signaling resilience in its operations. The company expects robust growth in its platelet segment, projecting an increase of 8% to 11% from 2023 revenue, supported by a strengthened sales force and successful engagements with hospital clients. Furthermore, Cerus reiterated its 2024 product revenue guidance of $172-175 million, indicating confidence in continued demand for its INTERCEPT Blood System products.

Bear case

Cerus Corporation has lowered its 2023 product revenue guidance to between $155 million and $158 million, reflecting a delay in executing a significant sales agreement, which indicates challenges in achieving projected sales growth. Adoption of Intercept-treated plasma is declining in importance, further compounding concerns about the company’s revenue drivers and overall market position. The inability to secure approval for Intercept-treated red blood cells could hinder profitability and market competitiveness, while ongoing geopolitical risks add additional uncertainty to the company’s financial outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.